vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:VTVT
- CUSIP: N/A
- Web: www.vtvtherapeutics.com
- Market Cap: $148.64 million
- Outstanding Shares: 9,693,000
- 50 Day Moving Avg: $4.58
- 200 Day Moving Avg: $5.25
- 52 Week Range: $3.57 - $7.50
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.81
- P/E Growth: 0.00
- Annual Revenue: $119,000.00
- Price / Sales: 368.99
- Book Value: ($10.98) per share
- Price / Book: -0.41
- EBIDTA: ($52,990,000.00)
- Net Margins: -13,635.29%
- Return on Assets: -33.58%
- Current Ratio: 2.95%
- Quick Ratio: 2.95%
- Average Volume: 24,747 shs.
- Beta: 0.92
- Short Ratio: 9.39
Frequently Asked Questions for vTv Therapeutics (NASDAQ:VTVT)
What is vTv Therapeutics' stock symbol?
vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."
How were vTv Therapeutics' earnings last quarter?
vTv Therapeutics Inc. (NASDAQ:VTVT) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.02. The company earned $0.01 million during the quarter, compared to the consensus estimate of $0.19 million. View vTv Therapeutics' Earnings History.
When will vTv Therapeutics make its next earnings announcement?
Where is vTv Therapeutics' stock going? Where will vTv Therapeutics' stock price be in 2017?
4 analysts have issued 1-year price targets for vTv Therapeutics' shares. Their predictions range from $13.00 to $24.00. On average, they anticipate vTv Therapeutics' share price to reach $16.50 in the next year. View Analyst Ratings for vTv Therapeutics.
What are analysts saying about vTv Therapeutics stock?
Here are some recent quotes from research analysts about vTv Therapeutics stock:
- 1. According to Zacks Investment Research, "vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. " (8/19/2017)
- 2. Canaccord Genuity analysts commented, "We reiterate our BUY. Pivotal Ph3 azeliragon Alzheimer trials enrollment complete: Part A to deliver data in 1H18 and Part B in 2H. Mgmt. announced Ph3 STEADFAST Part B completed enrollment, including 20-25% ROW pts. Conducted under Special Protocol Assessment, STEADFAST is an 18-month, randomized, double-blind, placebo-controlled study assessing oral, once- daily azeliragon’s effect on cognitive/functional decline in 400 mild Alzheimer’s Disease (AD) pts. on standard-of-care (SOC; acetylcholinesterase inhibitor and/or memantine). Co-primary endpoints include change in AD Assessment Scale-cognitive subscale (ADAS- Cog11) and Clinical Dementia Rating Scale Sum of Boxes (CDR-sb). Part A completed enrollment in mid-16. In a Ph2b trial assessing SOC +/- 5mg azeliragon at 18 months, daily azeliragon was well-tolerated and had significantly lower ADAS-Cog11 and CDR-sb score decline, with greater benefit in mild patients, and significantly fewer psychiatric events." (8/4/2017)
Who are some of vTv Therapeutics' key competitors?
Some companies that are related to vTv Therapeutics include Corbus Pharmaceuticals Holdings (CRBP), BioTime (BTX), Merus N.V. (MRUS), CymaBay Therapeutics (CBAY), Rigel Pharmaceuticals (RIGL), Oxford BioMedica plc (OXB), Bellicum Pharmaceuticals (BLCM), Minerva Neurosciences (NERV), Circassia Pharmaceuticals PLC (CIR), DURECT Corporation (DRRX), Catalyst Pharmaceuticals (CPRX), Urogen Pharma (URGN), Ardelyx (ARDX), Pieris Pharmaceuticals (PIRS), uniQure N.V. (QURE), Tocagen (TOCA), Chimerix (CMRX) and ObsEva SA (OBSV).
Who are vTv Therapeutics' key executives?
vTv Therapeutics' management team includes the folowing people:
- Jeffrey B. Kindler, Executive Chairman of the Board
- Stephen L. Holcombe, President, Chief Executive Officer
- Rudy C. Howard CPA, Chief Financial Officer, Executive Vice President
- Larry Douglas Altstiel M.D. Ph.D., Chief Medical Officer
- Steven M. Cohen, Director
- Paul M. Meister, Director
- Paul G. Savas, Director
- Howard L. Weiner, Director
- John A. Fry, Independent Director
When did vTv Therapeutics IPO?
(VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.
Who owns vTv Therapeutics stock?
vTv Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include
MACANDREWS & FORBES INC.
(78.10%), Franklin Resources Inc. (2.74%), Sphera Funds Management LTD. (0.91%), Ameriprise Financial Inc. (0.81%), Vanguard Group Inc. (0.78%) and Candriam Luxembourg S.C.A. (1.44%). Company insiders that own vTv Therapeutics stock include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.
Who sold vTv Therapeutics stock? Who is selling vTv Therapeutics stock?
Who bought vTv Therapeutics stock? Who is buying vTv Therapeutics stock?
vTv Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc. and State Street Corp. Company insiders that have bought vTv Therapeutics stock in the last two years include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.
How do I buy vTv Therapeutics stock?
Shares of vTv Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is vTv Therapeutics' stock price today?
MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of vTv Therapeutics stock can currently be purchased for approximately $4.53.
Earnings History for vTv Therapeutics (NASDAQ:VTVT)Earnings History by Quarter for vTv Therapeutics (NASDAQ VTVT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||Q2 2017||($0.43)||($0.41)||$0.19 million||$0.01 million||View||N/A|
|5/3/2017||Q1 2017||($0.44)||($0.44)||$0.20 million||$0.03 million||View||N/A|
|3/1/2016||Q4||($0.47)||($0.35)||$0.03 million||$0.23 million||View||N/A|
Earnings Estimates for vTv Therapeutics (NASDAQ:VTVT)
Current Year EPS Consensus Estimate: $-1.41 EPS
Next Year EPS Consensus Estimate: $-1.61 EPS
Dividend History for vTv Therapeutics (NASDAQ:VTVT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for vTv Therapeutics (NASDAQ:VTVT)
Insider Ownership Percentage: 0.80%Insider Trades by Quarter for vTv Therapeutics (NASDAQ:VTVT)
Institutional Ownership Percentage: 11.16%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/16/2017||Ronald O Perelman||Major Shareholder||Buy||10,000||$4.97||$49,700.00|| |
|8/15/2017||Ronald O Perelman||Major Shareholder||Buy||50,000||$4.72||$236,000.00|| |
|8/11/2017||Ronald O Perelman||Major Shareholder||Buy||85,000||$4.13||$351,050.00|| |
|5/15/2017||Paul G Savas||Director||Buy||3,000||$5.18||$15,540.00|| |
|3/31/2017||Paul G Savas||Director||Buy||10,000||$6.50||$65,000.00|| |
|5/27/2016||Paul G Savas||Director||Buy||6,000||$5.67||$34,020.00|| |
|5/24/2016||Paul G Savas||Director||Buy||1,259||$5.26||$6,622.34|| |
|4/8/2016||Ronald O Perelman||Major Shareholder||Buy||10,000||$4.99||$49,900.00|| |
|4/5/2016||Ronald O Perelman||Major Shareholder||Buy||400,000||$5.20||$2,080,000.00|| |
|3/28/2016||Paul G Savas||Director||Buy||10,000||$5.35||$53,500.00|| |
|3/24/2016||Ronald O Perelman||Major Shareholder||Buy||10,000||$5.64||$56,400.00|| |
|3/7/2016||Paul G Savas||Director||Buy||15,000||$5.82||$87,300.00|| |
|2/12/2016||Ronald O Perelman||Major Shareholder||Buy||10,000||$5.83||$58,300.00|| |
|2/5/2016||Ronald O Perelman||Major Shareholder||Buy||10,000||$6.43||$64,300.00|| |
|2/4/2016||Ronald O Perelman||Major Shareholder||Buy||20,000||$6.05||$121,000.00|| |
|1/13/2016||Ronald O Perelman||Major Shareholder||Buy||15,000||$6.41||$96,150.00|| |
|12/18/2015||Ronald O Perelman||Major Shareholder||Buy||15,000||$6.40||$96,000.00|| |
|12/15/2015||Noel Joseph Spiegel||Director||Buy||5,710||$6.20||$35,402.00|| |
|10/2/2015||Ronald O Perelman||Major Shareholder||Buy||30,000||$6.26||$187,800.00|| |
|9/28/2015||Ronald O Perelman||Major Shareholder||Buy||40,000||$6.04||$241,600.00|| |
|9/25/2015||Paul G Savas||Director||Buy||5,000||$6.62||$33,100.00|| |
|9/22/2015||Ronald O Perelman||Major Shareholder||Buy||24,000||$6.82||$163,680.00|| |
Headline Trends for vTv Therapeutics (NASDAQ:VTVT)
Latest Headlines for vTv Therapeutics (NASDAQ:VTVT)
|vTv Therapeutics Inc. (VTVT) Downgraded to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - August 19 at 8:30 AM
|vTv Therapeutics Inc. (VTVT) Major Shareholder Ronald O. Perelman Purchases 10,000 Shares|
www.americanbankingnews.com - August 16 at 9:34 PM
|Insider Buying: vTv Therapeutics Inc. (VTVT) Major Shareholder Purchases 50,000 Shares of Stock|
www.americanbankingnews.com - August 15 at 7:40 PM
|Insider Buying: vTv Therapeutics Inc. (VTVT) Major Shareholder Acquires 85,000 Shares of Stock|
www.americanbankingnews.com - August 14 at 11:10 PM
|vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - August 8 at 2:36 PM
| Analysts Expect vTv Therapeutics Inc. (VTVT) Will Announce Quarterly Sales of $200,000.00|
www.americanbankingnews.com - August 8 at 7:44 AM
|vTv Therapeutics Inc. (NASDAQ:VTVT) PT Set at $13.00 by HC Wainwright|
www.americanbankingnews.com - August 6 at 10:26 PM
|-$0.44 EPS Expected for vTv Therapeutics Inc. (VTVT) This Quarter|
www.americanbankingnews.com - August 6 at 12:28 PM
|vTv Therapeutics Inc. (VTVT) Announces Earnings Results|
www.americanbankingnews.com - August 4 at 3:52 PM
|vTv Therapeutics Inc. (VTVT) Earns "Buy" Rating from Canaccord Genuity|
www.americanbankingnews.com - August 4 at 1:48 PM
|vTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results|
finance.yahoo.com - August 3 at 8:48 AM
|VTv Therapeutics reports 2Q loss|
finance.yahoo.com - August 3 at 8:47 AM
|vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon|
finance.yahoo.com - August 3 at 8:47 AM
|'We're not going to be taken off' — vTv Therapeutics CEO responds to NASDAQ's delisting warning|
finance.yahoo.com - July 21 at 8:32 AM
|vTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference|
finance.yahoo.com - July 14 at 9:52 AM
|Triad pharma company's stock could be delisted|
www.bizjournals.com - July 6 at 10:18 PM
|vTv Therapeutics Inc. (VTVT) Lowered to "Sell" at Zacks Investment Research|
www.americanbankingnews.com - July 5 at 1:21 PM
|vTv Therapeutics Inc. (VTVT) Upgraded to "Buy" at Zacks Investment Research|
www.americanbankingnews.com - June 24 at 9:32 AM
|vTv Therapeutics Inc. (VTVT) Downgraded to Hold at Zacks Investment Research|
www.americanbankingnews.com - June 23 at 7:42 AM
|vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions|
finance.yahoo.com - June 11 at 11:40 PM
|vTv Therapeutics to Present Two Posters at the American Diabetes Association’s 77th Scientific Sessions|
finance.yahoo.com - June 9 at 2:21 AM
|vTv Therapeutics Completes Enrollment of Part B of Pivotal Phase III STEADFAST Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease|
finance.yahoo.com - June 2 at 6:01 AM
|vTv Therapeutics Inc (VTVT) Rating Increased to Buy at Zacks Investment Research|
www.americanbankingnews.com - June 1 at 8:34 AM
|vTv Therapeutics Inc (VTVT) Downgraded by Zacks Investment Research to "Hold"|
www.americanbankingnews.com - May 30 at 10:14 PM
|ETFs with exposure to vTv Therapeutics, Inc. : May 22, 2017|
finance.yahoo.com - May 22 at 7:38 PM
|Paul G. Savas Acquires 3,000 Shares of vTv Therapeutics Inc (VTVT) Stock|
www.americanbankingnews.com - May 15 at 10:34 PM
|vTv Therapeutics Inc (VTVT) Given a $13.00 Price Target by HC Wainwright Analysts|
www.americanbankingnews.com - May 7 at 7:42 AM
|vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017|
finance.yahoo.com - May 6 at 1:29 AM
|vTv Therapeutics Inc (VTVT) Releases Quarterly Earnings Results, Hits Expectations|
www.americanbankingnews.com - May 5 at 2:31 PM
|ETFs with exposure to vTv Therapeutics, Inc. : May 4, 2017|
finance.yahoo.com - May 5 at 3:30 AM
|vTv Therapeutics Reports First Quarter 2017 Financial and Operational Results|
finance.yahoo.com - May 3 at 6:54 PM
|VTv Therapeutics reports 1Q loss|
finance.yahoo.com - May 3 at 6:54 PM
|vTv Therapeutics (VTVT) Given Coverage Optimism Rating of -0.39|
www.americanbankingnews.com - May 2 at 1:18 PM
|vTv Therapeutics Inc (VTVT) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - April 27 at 11:40 PM
|vTv Therapeutics (VTVT) Receives Coverage Optimism Score of 0.31|
www.americanbankingnews.com - April 27 at 11:54 AM
|vTv Therapeutics (VTVT) Earns News Sentiment Rating of 0.31|
www.americanbankingnews.com - April 20 at 3:06 PM
|vTv Therapeutics (VTVT) Receives News Impact Score of -0.10|
www.americanbankingnews.com - April 13 at 1:18 PM
|vTv Therapeutics Inc (VTVT) Short Interest Update|
www.americanbankingnews.com - April 7 at 8:00 PM
|ETFs with exposure to vTv Therapeutics, Inc. : April 5, 2017|
finance.yahoo.com - April 7 at 1:25 PM
|vTv Therapeutics' (VTVT) Buy Rating Reaffirmed at HC Wainwright|
www.americanbankingnews.com - April 5 at 8:58 AM
|HC Wainwright Reaffirms Buy Rating for vTv Therapeutics Inc (VTVT)|
www.americanbankingnews.com - April 4 at 9:14 AM
|vTv Therapeutics Inc (VTVT) Director Purchases $65,000.00 in Stock|
www.americanbankingnews.com - April 3 at 8:26 PM
|vTv Therapeutics Inc (VTVT) Receives Overweight Rating from Piper Jaffray Companies|
www.americanbankingnews.com - March 30 at 6:22 PM
|HC Wainwright Reiterates "Buy" Rating for vTv Therapeutics Inc (VTVT)|
www.americanbankingnews.com - March 30 at 9:05 AM
|VTV THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
biz.yahoo.com - March 29 at 10:09 AM
|vTv Therapeutics to Present at Two Upcoming Annual Investor Conferences|
finance.yahoo.com - March 11 at 11:07 AM
|vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights|
us.rd.yahoo.com - February 28 at 11:07 AM
|VTV THERAPEUTICS INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - February 25 at 4:20 AM
|vTv Therapeutics (VTVT) in Focus: Stock Moves 6.7% Higher|
finance.yahoo.com - January 25 at 4:27 PM
|vTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes|
us.rd.yahoo.com - December 15 at 7:13 AM
vTv Therapeutics (VTVT) Chart for Sunday, August, 20, 2017